- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Hypertrophic cardiomyopathy
- Meeting Date: November 2022
- Public Summary Document (PSD) November 2022 PBAC Meeting - (PDF 1.2MB)
- Public Summary Document (PSD) November 2022 PBAC Meeting - (Word 398KB)
Mavacamten – November 2022
Mavacamten: Capsule 2.5 mg, Capsule 5 mg, Capsule 10 mg, Capsule 15 mg; Camzyos®
Last updated
17 March 2023